NovoCure Limited (NVCR)
Total Valuation
NovoCure has a market cap or net worth of $1.69 billion. The enterprise value is $1.38 billion.
Market Cap | 1.69B |
Enterprise Value | 1.38B |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, before market open.
Earnings Date | May 2, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 107.09 million shares outstanding. The number of shares has increased by 1.65% in one year.
Shares Outstanding | 107.09M |
Shares Change (YoY) | +1.65% |
Shares Change (QoQ) | +0.13% |
Owned by Insiders (%) | 1.67% |
Owned by Institutions (%) | 85.89% |
Float | 95.92M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 909.09 |
PS Ratio | 3.32 |
Forward PS | 3.07 |
PB Ratio | 4.67 |
P/FCF Ratio | n/a |
PEG Ratio | -0.47 |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 2.70 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.78, with a Debt / Equity ratio of 1.64.
Current Ratio | 5.78 |
Quick Ratio | 5.56 |
Debt / Equity | 1.64 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | 5.66 |
Financial Efficiency
Return on equity (ROE) is -51.60% and return on invested capital (ROIC) is -24.29%.
Return on Equity (ROE) | -51.60% |
Return on Assets (ROA) | -17.90% |
Return on Capital (ROIC) | -24.29% |
Revenue Per Employee | $350,542 |
Profits Per Employee | -$142,493 |
Employee Count | 1,453 |
Asset Turnover | 0.44 |
Inventory Turnover | 3.80 |
Taxes
In the past 12 months, NovoCure has paid $15.30 million in taxes.
Income Tax | 15.30M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.94% in the last 52 weeks. The beta is 0.41, so NovoCure's price volatility has been lower than the market average.
Beta (1Y) | 0.41 |
52-Week Price Change | -72.94% |
50-Day Moving Average | 14.94 |
200-Day Moving Average | 20.57 |
Relative Strength Index (RSI) | 56.92 |
Average Volume (30 Days) | 1,382,672 |
Short Selling Information
The latest short interest is 5.54 million, so 5.17% of the outstanding shares have been sold short.
Short Interest | 5.54M |
Short Previous Month | 5.64M |
Short % of Shares Out | 5.17% |
Short % of Float | 5.78% |
Short Ratio (days to cover) | 5.25 |
Income Statement
In the last 12 months, NovoCure had revenue of $509.34 million and -$207.04 million in losses. Loss per share was -$1.95.
Revenue | 509.34M |
Gross Profit | 381.06M |
Operating Income | -232.87M |
Pretax Income | -191.74M |
Net Income | -207.04M |
EBITDA | -221.90M |
EBIT | -232.87M |
Loss Per Share | -$1.95 |
Balance Sheet
The company has $912.36 million in cash and $596.24 million in debt, giving a net cash position of $316.12 million or $2.95 per share.
Cash & Cash Equivalents | 912.36M |
Total Debt | 596.24M |
Net Cash | 316.12M |
Net Cash Per Share | $2.95 |
Equity / Book Value | 362.50M |
Book Value Per Share | 3.38 |
Working Capital | 855.29M |
Cash Flow
In the last 12 months, operating cash flow was -$73.34 million and capital expenditures -$27.09 million, giving a free cash flow of -$100.43 million.
Operating Cash Flow | -73.34M |
Capital Expenditures | -27.09M |
Free Cash Flow | -100.43M |
FCF Per Share | -$0.94 |
Margins
Gross margin is 74.81%, with operating and profit margins of -45.72% and -40.65%.
Gross Margin | 74.81% |
Operating Margin | -45.72% |
Pretax Margin | -37.64% |
Profit Margin | -40.65% |
EBITDA Margin | -43.57% |
EBIT Margin | -45.72% |
FCF Margin | -19.72% |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.65% |
Shareholder Yield | -1.65% |
Earnings Yield | -12.24% |
FCF Yield | -5.94% |
Analyst Forecast
The average price target for NovoCure is $48.56, which is 210.69% higher than the current price. The consensus rating is "Buy".
Price Target | $48.56 |
Price Target Difference | 210.69% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Revenue Growth Forecast (5Y) | 10.64% |
EPS Growth Forecast (5Y) | -7.21% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.76 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.76 |
Piotroski F-Score | 1 |